BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: James MH, Campbell EJ, Dayas CV. Role of the Orexin/Hypocretin System in Stress-Related Psychiatric Disorders. Curr Top Behav Neurosci 2017;33:197-219. [PMID: 28083790 DOI: 10.1007/7854_2016_56] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang H, Liang B, Li T, Zhou Y, Shang D, Du Z. Orexin A Suppresses Oxidized LDL Induced Endothelial Cell Inflammation via MAPK p38 and NF-κB Signaling Pathway: OREXIN A SUPPRESSES ENDOTHELIAL CELL INFLAMMATION. IUBMB Life 2018;70:961-8. [DOI: 10.1002/iub.1890] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
2 Boss C, Roch C. Orexin research: patent news from 2016. Expert Opinion on Therapeutic Patents 2017;27:1123-33. [DOI: 10.1080/13543776.2017.1344221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
3 Sartori SB, Singewald N. Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacol Ther 2019;204:107402. [PMID: 31470029 DOI: 10.1016/j.pharmthera.2019.107402] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 14.7] [Reference Citation Analysis]
4 Alijanpour S, Khakpai F, Ebrahimi-ghiri M, Zarrindast M. Co-administration of the low dose of orexin and nitrergic antagonists induces an antidepressant-like effect in mice. Biomedicine & Pharmacotherapy 2019;109:589-94. [DOI: 10.1016/j.biopha.2018.10.033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
5 Wang D, Li A, Dong K, Li H, Guo Y, Zhang X, Cai M, Li H, Zhao G, Yang Q. Lateral hypothalamus orexinergic inputs to lateral habenula modulate maladaptation after social defeat stress. Neurobiol Stress 2021;14:100298. [PMID: 33569507 DOI: 10.1016/j.ynstr.2021.100298] [Reference Citation Analysis]
6 Coccurello R. Anhedonia in depression symptomatology: Appetite dysregulation and defective brain reward processing. Behavioural Brain Research 2019;372:112041. [DOI: 10.1016/j.bbr.2019.112041] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
7 Grafe LA, Geng E, Corbett B, Urban K, Bhatnagar S. Sex- and Stress-Dependent Effects on Dendritic Morphology and Spine Densities in Putative Orexin Neurons. Neuroscience 2019;418:266-78. [PMID: 31442567 DOI: 10.1016/j.neuroscience.2019.08.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
8 Huang M, Chen C, Chen L, Chang H, Chen C, Lin S, Xu K. Chronic ketamine abuse is associated with orexin-A reduction and ACTH elevation. Psychopharmacology 2020;237:45-53. [DOI: 10.1007/s00213-019-05342-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
9 Campbell EJ, Marchant NJ, Lawrence AJ. A sleeping giant: Suvorexant for the treatment of alcohol use disorder? Brain Res 2020;1731:145902. [PMID: 30081035 DOI: 10.1016/j.brainres.2018.08.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
10 Grafe LA, Bhatnagar S. The contribution of orexins to sex differences in the stress response. Brain Res 2020;1731:145893. [PMID: 30081036 DOI: 10.1016/j.brainres.2018.07.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
11 James MH, Campbell EJ, Dayas CV. Role of the Orexin/Hypocretin System in Stress-Related Psychiatric Disorders. Curr Top Behav Neurosci 2017;33:197-219. [PMID: 28083790 DOI: 10.1007/7854_2016_56] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 11.0] [Reference Citation Analysis]
12 Jacobson LH, Hoyer D, de Lecea L. Hypocretins (orexins): The ultimate translational neuropeptides. J Intern Med 2022. [PMID: 35043499 DOI: 10.1111/joim.13406] [Reference Citation Analysis]
13 Navarro G, Medrano M, Aguinaga D, Vega-Quiroga I, Lillo A, Jiménez J, Casanovas M, Canela EI, Mallol J, Gysling K, Franco R. Differential effect of amphetamine over the corticotropin-releasing factor CRF2 receptor, the orexin OX1 receptor and the CRF2-OX1 heteroreceptor complex. Neuropharmacology 2019;152:102-11. [PMID: 30465812 DOI: 10.1016/j.neuropharm.2018.11.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
14 Campbell EJ, Norman A, Bonomo Y, Lawrence AJ. Suvorexant to treat alcohol use disorder and comorbid insomnia: Plan for a phase II trial. Brain Res 2020;1728:146597. [PMID: 31837287 DOI: 10.1016/j.brainres.2019.146597] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
15 James MH, Fragale JE, Aurora RN, Cooperman NA, Langleben DD, Aston-Jones G. Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer? Neuropsychopharmacology 2020;45:717-9. [PMID: 31986520 DOI: 10.1038/s41386-020-0619-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
16 Stanojlovic M, Pallais JP, Lee MK, Kotz CM. Pharmacological and chemogenetic orexin/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinson's disease. Mol Brain 2019;12:87. [PMID: 31666100 DOI: 10.1186/s13041-019-0514-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
17 Summers CH, Yaeger JDW, Staton CD, Arendt DH, Summers TR. Orexin/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: Potential for therapy. Brain Res 2020;1731:146085. [PMID: 30590027 DOI: 10.1016/j.brainres.2018.12.036] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
18 Matzeu A, Martin-Fardon R. Cocaine-Seeking Behavior Induced by Orexin A Administration in the Posterior Paraventricular Nucleus of the Thalamus Is Not Long-Lasting: Neuroadaptation of the Orexin System During Cocaine Abstinence. Front Behav Neurosci 2021;15:620868. [PMID: 33708078 DOI: 10.3389/fnbeh.2021.620868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Altamura C, Corbelli I, de Tommaso M, Di Lorenzo C, Di Lorenzo G, Di Renzo A, Filippi M, Jannini TB, Messina R, Parisi P, Parisi V, Pierelli F, Rainero I, Raucci U, Rubino E, Sarchielli P, Li L, Vernieri F, Vollono C, Coppola G. Pathophysiological Bases of Comorbidity in Migraine. Front Hum Neurosci 2021;15:640574. [PMID: 33958992 DOI: 10.3389/fnhum.2021.640574] [Reference Citation Analysis]
20 Matzeu A, Martin-Fardon R. Targeting the orexin system for prescription opioid use disorder: Orexin-1 receptor blockade prevents oxycodone taking and seeking in rats. Neuropharmacology 2020;164:107906. [PMID: 31841797 DOI: 10.1016/j.neuropharm.2019.107906] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
21 Han Y, Yuan K, Zheng Y, Lu L. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders. Neurosci Bull 2020;36:432-48. [PMID: 31782044 DOI: 10.1007/s12264-019-00447-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
22 Gołyszny M, Zieliński M, Paul-samojedny M, Filipczyk Ł, Pałasz A, Obuchowicz E. Escitalopram alters the hypothalamic OX system but does not affect its up-regulation induced by early-life stress in adult rats. Neuroscience Research 2022. [DOI: 10.1016/j.neures.2022.02.005] [Reference Citation Analysis]
23 Huang S, Zhao Z, Ma J, Hu S, Li L, Wang Z, Sun W, Shi X, Li M, Zheng J. Increased plasma orexin-A concentrations are associated with the non-motor symptoms in Parkinson's disease patients. Neurosci Lett 2021;741:135480. [PMID: 33161104 DOI: 10.1016/j.neulet.2020.135480] [Reference Citation Analysis]
24 Yaeger JD, Krupp KT, Jacobs BM, Onserio BO, Meyerink BL, Cain JT, Ronan PJ, Renner KJ, Dileone RJ, Summers CH. Orexin 1 Receptor Antagonism in the Basolateral Amygdala Shifts the Balance from Pro- to Anti-stress Signaling and Behavior. Biological Psychiatry 2022. [DOI: 10.1016/j.biopsych.2021.12.019] [Reference Citation Analysis]
25 Ikeno T, Yan L. A comparison of the orexin receptor distribution in the brain between diurnal Nile grass rats (Arvicanthis niloticus) and nocturnal mice (Mus musculus). Brain Res 2018;1690:89-95. [PMID: 29630859 DOI: 10.1016/j.brainres.2018.04.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
26 Coppola G, Di Renzo A, Petolicchio B, Tinelli E, Di Lorenzo C, Serrao M, Calistri V, Tardioli S, Cartocci G, Parisi V, Caramia F, Di Piero V, Pierelli F. Increased neural connectivity between the hypothalamus and cortical resting-state functional networks in chronic migraine. J Neurol 2020;267:185-91. [PMID: 31606759 DOI: 10.1007/s00415-019-09571-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
27 Moorman DE. The hypocretin/orexin system as a target for excessive motivation in alcohol use disorders. Psychopharmacology (Berl) 2018;235:1663-80. [PMID: 29508004 DOI: 10.1007/s00213-018-4871-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
28 Turku A, Leino TO, Karhu L, Yli-Kauhaluoma J, Kukkonen JP, Wallén EAA, Xhaard H. Structure-Activity Relationships of 1-Benzoylazulenes at the OX1 and OX2 Orexin Receptors. ChemMedChem 2019;14:965-81. [PMID: 30892823 DOI: 10.1002/cmdc.201900074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Kirsch M. On the Abilities of Unconscious Freudian Motivational Drives to Evoke Conscious Emotions. Front Psychol 2019;10:470. [PMID: 30899234 DOI: 10.3389/fpsyg.2019.00470] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Morales-mulia M. Intra-accumbal orexin-1 receptor inhibition prevents the anxiolytic-like effect of ethanol and leads to increases in orexin-A content and receptor expression. Pharmacology Biochemistry and Behavior 2019;185:172761. [DOI: 10.1016/j.pbb.2019.172761] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
31 Dimatelis JJ, Mtintsilana A, Naidoo V, Stein DJ, Russell VA. Chronic light exposure alters serotonergic and orexinergic systems in the rat brain and reverses maternal separation-induced increase in orexin receptors in the prefrontal cortex. Metab Brain Dis 2018;33:433-41. [DOI: 10.1007/s11011-017-0123-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
32 D'Souza MS. Brain and Cognition for Addiction Medicine: From Prevention to Recovery Neural Substrates for Treatment of Psychostimulant-Induced Cognitive Deficits. Front Psychiatry 2019;10:509. [PMID: 31396113 DOI: 10.3389/fpsyt.2019.00509] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
33 Yeoh JW, James MH, Adams CD, Bains JS, Sakurai T, Aston-Jones G, Graham BA, Dayas CV. Activation of lateral hypothalamic group III metabotropic glutamate receptors suppresses cocaine-seeking following abstinence and normalizes drug-associated increases in excitatory drive to orexin/hypocretin cells. Neuropharmacology 2019;154:22-33. [PMID: 30253175 DOI: 10.1016/j.neuropharm.2018.09.033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
34 Hook M, Xu F, Terenina E, Zhao W, Starlard-Davenport A, Mormede P, Jones BC, Mulligan MK, Lu L. Exploring the involvement of Tac2 in the mouse hippocampal stress response through gene networking. Gene 2019;696:176-85. [PMID: 30769143 DOI: 10.1016/j.gene.2019.02.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 James MH, Aston-Jones G. Introduction to the Special Issue: "Making orexin-based therapies for addiction a reality: What are the steps from here?". Brain Res 2020;1731:146665. [PMID: 31930996 DOI: 10.1016/j.brainres.2020.146665] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
36 Matzeu A, Martin-Fardon R. Targeting the Orexin System for Prescription Opioid Use Disorder. Brain Sci 2020;10:E226. [PMID: 32290110 DOI: 10.3390/brainsci10040226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
37 Stanojlovic M, Pallais JP, Kotz CM. Chemogenetic Modulation of Orexin Neurons Reverses Changes in Anxiety and Locomotor Activity in the A53T Mouse Model of Parkinson's Disease. Front Neurosci 2019;13:702. [PMID: 31417337 DOI: 10.3389/fnins.2019.00702] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
38 Ketchesin KD, Becker-Krail D, McClung CA. Mood-related central and peripheral clocks. Eur J Neurosci 2020;51:326-45. [PMID: 30402924 DOI: 10.1111/ejn.14253] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
39 Herring WJ, Roth T, Krystal AD, Michelson D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res 2018;28. [DOI: 10.1111/jsr.12782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
40 James MH, Mahler SV, Moorman DE, Aston-Jones G. A Decade of Orexin/Hypocretin and Addiction: Where Are We Now? Curr Top Behav Neurosci 2017;33:247-81. [PMID: 28012090 DOI: 10.1007/7854_2016_57] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 16.0] [Reference Citation Analysis]
41 Hopf FW. Recent perspectives on orexin/hypocretin promotion of addiction-related behaviors. Neuropharmacology 2020;168:108013. [PMID: 32092435 DOI: 10.1016/j.neuropharm.2020.108013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
42 Khairuddin S, Aquili L, Heng BC, Hoo TLC, Wong KH, Lim LW. Dysregulation of the orexinergic system: A potential neuropeptide target in depression. Neuroscience & Biobehavioral Reviews 2020;118:384-96. [DOI: 10.1016/j.neubiorev.2020.07.040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
43 Staton CD, Yaeger JDW, Khalid D, Haroun F, Fernandez BS, Fernandez JS, Summers BK, Summers TR, Sathyanesan M, Newton SS, Summers CH. Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression. Neuropharmacology 2018;143:79-94. [PMID: 30240784 DOI: 10.1016/j.neuropharm.2018.09.016] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
44 James MH, Fragale JE, O'Connor SL, Zimmer BA, Aston-Jones G. The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse. Neuropharmacology 2021;183:108359. [PMID: 33091458 DOI: 10.1016/j.neuropharm.2020.108359] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
45 Bowrey HE, James MH, Aston-Jones G. New directions for the treatment of depression: Targeting the photic regulation of arousal and mood (PRAM) pathway. Depress Anxiety 2017;34:588-95. [PMID: 28489327 DOI: 10.1002/da.22635] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
46 Dingemanse J, Charef P, Black J, Gouws C. Investigation of the effect of the dual orexin receptor antagonist almorexant on ophthalmological, spermatogenic, and hormonal variables in healthy male subjects. Biomed Pharmacother 2021;133:110955. [PMID: 33190032 DOI: 10.1016/j.biopha.2020.110955] [Reference Citation Analysis]
47 Peleg-Raibstein D, Burdakov D. Do orexin/hypocretin neurons signal stress or reward? Peptides 2021;145:170629. [PMID: 34416308 DOI: 10.1016/j.peptides.2021.170629] [Reference Citation Analysis]
48 Gyawali U, James MH. Orexin (Hypocretin) Signaling in the Basolateral Amygdala Contributes to Individual Differences in Stress Sensitivity. Biological Psychiatry 2022;91:775-7. [DOI: 10.1016/j.biopsych.2022.02.957] [Reference Citation Analysis]
49 Tsai MC, Huang TL. Orexin A in men with heroin use disorder undergoing methadone maintenance treatment. Psychiatry Res 2018;264:412-5. [PMID: 29680730 DOI: 10.1016/j.psychres.2018.04.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
50 Lamotte G, Shouman K, Benarroch EE. Stress and central autonomic network. Auton Neurosci 2021;235:102870. [PMID: 34461325 DOI: 10.1016/j.autneu.2021.102870] [Reference Citation Analysis]
51 Stanojlovic M, Pallais JP, Kotz CM. Inhibition of Orexin/Hypocretin Neurons Ameliorates Elevated Physical Activity and Energy Expenditure in the A53T Mouse Model of Parkinson's Disease. Int J Mol Sci 2021;22:E795. [PMID: 33466831 DOI: 10.3390/ijms22020795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Morales-Mulia S, Magdaleno-Madrigal VM, Nicolini H, Genis-Mendoza A, Morales-Mulia M. Orexin-A up-regulates dopamine D2 receptor and mRNA in the nucleus accumbens Shell. Mol Biol Rep 2020;47:9689-97. [PMID: 33170427 DOI: 10.1007/s11033-020-05979-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Muthmainah M, Gogos A, Sumithran P, Brown RM. Orexins (hypocretins): The intersection between homeostatic and hedonic feeding. J Neurochem 2021;157:1473-94. [PMID: 33608877 DOI: 10.1111/jnc.15328] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Li HT, Donegan DC, Peleg-Raibstein D, Burdakov D. Hypothalamic deep brain stimulation as a strategy to manage anxiety disorders. Proc Natl Acad Sci U S A 2022;119:e2113518119. [PMID: 35412900 DOI: 10.1073/pnas.2113518119] [Reference Citation Analysis]
55 Abounoori M, Maddah MM, Akbari E, Houshmand G, Ardeshiri MR. The Effect of Orexin Receptor Antagonism on Quinpirole-Induced Compulsive-Like Checking Behavior in Rats. Neurotox Res 2020;38:18-26. [PMID: 32207079 DOI: 10.1007/s12640-020-00196-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
56 Liguori G, Tafuri S, Miyoshi C, Yanagisawa M, Squillacioti C, De Pasquale V, Mirabella N, Vittoria A, Costagliola A. Localization of orexin B and orexin-2 receptor in the rat epididymis. Acta Histochem 2018;120:292-7. [PMID: 29496265 DOI: 10.1016/j.acthis.2018.02.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
57 Porcaro C, Di Renzo A, Tinelli E, Di Lorenzo G, Seri S, Di Lorenzo C, Parisi V, Caramia F, Fiorelli M, Di Piero V, Pierelli F, Coppola G. Hypothalamic structural integrity and temporal complexity of cortical information processing at rest in migraine without aura patients between attacks. Sci Rep 2021;11:18701. [PMID: 34548562 DOI: 10.1038/s41598-021-98213-3] [Reference Citation Analysis]
58 Stanojlovic M, Pallais Yllescas JP Jr, Mavanji V, Kotz C. Chemogenetic activation of orexin/hypocretin neurons ameliorates aging-induced changes in behavior and energy expenditure. Am J Physiol Regul Integr Comp Physiol 2019;316:R571-83. [PMID: 30726119 DOI: 10.1152/ajpregu.00383.2018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
59 Liguori C, Mercuri NB, Nuccetelli M, Izzi F, Bernardini S, Placidi F, Ferini-strambi L. Cerebrospinal Fluid Orexin Levels and Nocturnal Sleep Disruption in Alzheimer’s Disease Patients Showing Neuropsychiatric Symptoms. JAD 2018;66:993-9. [DOI: 10.3233/jad-180769] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
60 Anderson RI, Moorman DE, Becker HC. Contribution of Dynorphin and Orexin Neuropeptide Systems to the Motivational Effects of Alcohol. Handb Exp Pharmacol 2018;248:473-503. [PMID: 29526023 DOI: 10.1007/164_2018_100] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
61 Chiamulera C, Padovani L, Corsi M. Drug discovery for the treatment of substance use disorders: novel targets, repurposing, and the need for new paradigms. Curr Opin Pharmacol 2017;35:120-4. [PMID: 28874314 DOI: 10.1016/j.coph.2017.08.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
62 Stanojlovic M, Pallais Yllescas JP Jr, Vijayakumar A, Kotz C. Early Sociability and Social Memory Impairment in the A53T Mouse Model of Parkinson's Disease Are Ameliorated by Chemogenetic Modulation of Orexin Neuron Activity. Mol Neurobiol 2019;56:8435-50. [PMID: 31250383 DOI: 10.1007/s12035-019-01682-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]